Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Stage I Lung Cancer AJCC v8: early-phase trial registry

7 of 16 indexed Stage I Lung Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 7 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Stage I Lung Cancer AJCC v8: 16 US clinical trials tracked, 7 recruiting.

Stage I Lung Cancer AJCC v8 is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.

Enrollment posture brief

Registry condition stage-i-lung-cancer-ajcc-v8

OPEN 7 | RECR 44% | LATE 3 | EARLY 5 | RANK #1060 | SPON 7

Nearest open-share peer: Acute Respiratory Distress Syndrome (44% recruiting · 32 trials)

Adolescent62.5%Alcohol Intoxication56.3%Stage I Lung Cancer AJCC (th…44%AL Amyloidosis43.8%Allergy18.8%
Open-enrollment share among volume-matched conditions near Stage I Lung Cancer AJCC v8

Stage I Lung Cancer AJCC v8 lists 7 open slots (44% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage I Lung Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage I Lung Cancer AJCC v8 is recruiting below its size-band peers.

    7 of 16 indexed trials (43.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage I Lung Cancer AJCC v8 research.

    M.D. Anderson Cancer Center accounts for 7 of 16 trials (43.8%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Stage I Lung Cancer AJCC v8 enrolment sits around 100 participants.

    Median target enrolment is 100 among the 16 trials that report a genuine target (sentinel values excluded). 7 of those (43.8%) plan for fewer than 100 participants.

  4. Stage I Lung Cancer AJCC v8 research is mostly interventional.

    15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 24Phase 33

Open and recent trials

16 total, page 1 of 1

RECRUITING NA 400 participants

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

M.D. Anderson Cancer Center

NCT03948100

RECRUITING Phase 2 220 participants

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Roswell Park Cancer Institute

NCT04067830

RECRUITING NA 150 participants

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

Roswell Park Cancer Institute

NCT05292521

RECRUITING NA 100 participants

The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer

Thomas Jefferson University

NCT05502523

RECRUITING NA 100 participants

New York Better Breathing Study

Roswell Park Cancer Institute

NCT06869447

RECRUITING NA 70 participants

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

Northwestern University

NCT05802186

RECRUITING Phase 2 50 participants

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

NCT04789681

ACTIVE NOT RECRUITING Phase 3 544 participants

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

National Cancer Institute (NCI)

NCT03811002

ACTIVE NOT RECRUITING Phase 3 480 participants

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

National Cancer Institute (NCI)

NCT04214262

ACTIVE NOT RECRUITING Phase 3 403 participants

Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer

City of Hope Medical Center

NCT04428905

ACTIVE NOT RECRUITING Phase 2 140 participants

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

NCT03110978

ACTIVE NOT RECRUITING NA 98 participants

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

OHSU Knight Cancer Institute

NCT04946279

ACTIVE NOT RECRUITING 74 participants

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study

M.D. Anderson Cancer Center

NCT04430725

ACTIVE NOT RECRUITING NA 70 participants

Online Psychosocial Intervention in Improving Social Well-Being and Support in Women With Stage I-IV Non-small Cell Lung Cancer Undergoing Treatment

M.D. Anderson Cancer Center

NCT03731585

ACTIVE NOT RECRUITING Phase 2 45 participants

Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study

M.D. Anderson Cancer Center

NCT03634241

ACTIVE NOT RECRUITING Phase 1 34 participants

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

NCT04505267

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 3

Named interventions

Most-linked intervention names on Stage I Lung Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Questionnaire Administration Other
8 trials
Quality-of-Life Assessment Other
6 trials
Biospecimen Collection Procedure
5 trials
Best Practice Other
3 trials
Computed Tomography Procedure
3 trials
Informational Intervention Other
2 trials
Educational Intervention Other
2 trials
Positron Emission Tomography Procedure
2 trials

US sites by state

Facility locations filed on Stage I Lung Cancer AJCC v8 trials. A trial with sites in several states counts in each.

Texas 7 trials
New York 4 trials
California 3 trials
Arkansas 2 trials
Alaska 2 trials
Pennsylvania 1 trials
Oregon 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage I Lung Cancer AJCC v8 page

16 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage I Lung Cancer AJCC v8 condition card totals 16 registered trials; most-linked intervention Questionnaire Administration; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.